NeOnc Technologies Holdings (NTHI) Registration filing summary

Company overview and business model

• Clinical-stage biopharmaceutical company focused on novel drug delivery and drug candidates for brain cancers and CNS diseases.

• Lead products: NEO100 (intranasal perillyl alcohol) and NEO212 (temozolomide-perillyl alcohol conjugate), both targeting intracranial malignancies.

• NEO100 in Phase IIa trials for glioma and meningioma; NEO212 in Phase I/II for brain tumors and metastases.

• Pipeline includes additional CNS and oncology indications, with preclinical work in Parkinson’s disease and pediatric brain tumors.

• No commercial products or sales infrastructure; revenue to date is minimal and from humanitarian use.

Financial performance and metrics

• Net losses: $9.6M (nine months ended Sep 30, 2024), $14.9M (2023), $3.0M (2022); accumulated deficit of $48.4M as of Sep 30, 2024.

• Revenue: $63K (nine months 2024), $70K (2023), $20K (2022), all from non-core activities.

• R&D expenses: $2.0M (nine months 2024), $1.5M (2023), $1.2M (2022); legal/professional and G&A expenses increased with public company preparations.

• Cash: $1.3M as of Sep 30, 2024; shareholders’ deficit of $5.3M.

• Raised $17.7M in equity and $11.7M in notes since inception; recent private placements at $12–$16/share.

Use of proceeds and capital allocation

• No proceeds to company from direct listing; proceeds from recent private placements used for R&D, clinical trials, and operating expenses.

• Additional capital required for ongoing trials, regulatory submissions, and commercialization efforts.

• Line of credit and equity purchase agreement in place for up to $10M and $50M, respectively, to support future operations.